A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor.

Trial Profile

A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Mar 2011 Results were published in the Journal of the American Society of Nephrology, according to an Abbott media release.
    • 22 Nov 2010 Results were presented at the annual American Society of Nephrology, acoording to an Abbott media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top